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Objectives: Research is equivocal regarding endurance performance benefits of external nasal dilators, 9 
and currently research focusing on internal nasal dilators is non-existent. Both devices are used within 10 
competitive cycling. This study examined the influence of external and internal nasal dilation on 11 
cycling economy of motion and 20-km time trial performance. Design: The study utilised a 12 
randomised, counterbalanced cross-over design.  Methods: Fifteen trained cyclists completed three 13 
exercise sessions consisting of a 15 min standardised warm up and 20-km cycling time trial while 14 
wearing either a Breathe Right® external nasal dilator, Turbine® internal nasal dilator or no device 15 
(control). During the warm up, heart rate, ratings of perceived exertion and dyspnoea and expired 16 
gases were collected. During the time trial, heart rate, perceived exertion, and dyspnoea were collected 17 
at 4-km intervals and mean 20-km power output was recorded. Results: No differences were observed 18 
for mean 20-km power output between the internal (270±45 W) or external dilator (271±44 W) and 19 
control (272±44 W). No differences in the economy of motion were observed throughout the 15-min 20 
warm up between conditions. Conclusions: The Turbine® and Breathe Right® nasal dilators are 21 
ineffective at enhancing 20-km cycling time trial performance.  22 
Keywords: exercise performance; aerobic; exercise physiology; sport, dyspnoea  23 




Within sport, developing a competitive edge which provides additional speed or power to an 26 
athlete or conserves energy is of great interest. In endurance sports, the mechanics of respiration are 27 
often overlooked; however, provide an opportunity for manipulation which could result in improved 28 
performance. During intense exercise, redistribution of blood flow from locomotor muscles to those of 29 
respiration1-3 has been shown to decrease exercise tolerance4-6 and results in early termination of 30 
exercise.5, 7, 8 Furthermore, respiratory muscle fatigue can increase perceived exertion and dyspnoea, 31 
both negatively influencing exercise performance.4, 6, 9 Thus, interventions which aim to unload 32 
respiratory muscles during exercise have the potential to enhance performance10-12.  33 
During exercise, ventilation is achieved through both the oral and nasal passages with some 34 
27% of ventilation originating through the nasal passage during intense exercise (90% of maximal 35 
oxygen consumption).13 Due to the narrow cross-sectional area, the nasal valve is the flow-limiting 36 
segment during oral-nasal ventilation increasing respiratory resistance12, 14 which can lead to increased 37 
respiratory fatigue.3, 8, 15 Increasing nasal valve area decreases respiratory resistance and may result in 38 
enhancements in performance.10-12 External nasal dilator strips are commonly used by endurance 39 
athletes to increase the nasal valve area3, 16, 17 and have shown a 31% reduction in nasal airway 40 
resistance leading to a 50% decrease in the work of nasal breathing.18 These changes can increase 41 
exercise performance3,16 and economy of motion;19 however, these findings are not consistent within 42 
the literature.11 Internal nasal dilating systems, such as the Turbine® and Nozovent®, work from within 43 
the nose expanding the nostril walls laterally increasing the cross-sectional area of the nasal valve. 44 
Internal nasal dilation is more effective at lowering nasal resistance than external methods19 thus may 45 
present a novel method to reduce airway resistance during exercise and improve performance. To the 46 
authors’ knowledge, no studies have been conducted to determine the performance benefits of internal 47 
nasal dilation.   48 
The purpose of the current study was to examine the influence of internal and external nasal 49 
dilation on 20-km cycling time trial performance in trained cyclists. Specifically, we examined the 50 
Breathe Right® external nasal dilator and the Turbine® internal nasal dilator as both devices are 51 
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currently used within competitive cycling. We hypothesised that compared with a control condition 52 
both nasal dilators would improve performance during a 20-km cycling time trial with internal nasal 53 
dilation resulting in superior performance compared with external dilation. We also hypothesised that 54 
the internal and external nasal dilators would decrease perception exertion, and dyspnoea during, and 55 
reduce respiratory muscle fatigue following a 20-km time trial. 56 




Fifteen male participants volunteered to for this study (age: 40 ± 10.5 y; height: 181.1 ± 4.3 59 
cm; weight: 78.50 ± 7.25 kg; maximal oxygen consumption: 60.7 ± 10.6 ml∙kg-1.min-1). At the time of 60 
data collection, all participants were cycling at least 150km per week and had previous racing/time-61 
trialling experience. Also, participants were required to meet the minimum standard for maximal 62 
oxygen consumption of 55.0 ml.kg-1.min-1 for inclusion into the study. The risks and benefits of 63 
participation were provided in writing, and informed consent was obtained prior to data collection. 64 
This study received ethical approval from the necessary institution prior to commencement and 65 
conformed to the Code of Ethics of the World Medical Association (Declaration of Helsinki).  66 
This study utilised a randomised, counterbalanced cross-over design. Participants were 67 
required to attend four laboratory sessions with no less than two days and no greater than ten days 68 
between sessions. All cycling was completed using an electronically braked cycle ergometer 69 
(Velotron, Racermate, USA) in a temperature control environmental chamber at 24⁰C and 40% 70 
relative humidity. During the initial session (familiarisation), participants completed a 15 min 71 
standardised cycling warm-up (five min at 75 W, five min at 150 W and five min at 200 W) followed 72 
five min later by a 20-km cycling time trial. During the time trial, power output was recorded at a 73 
frequency of 1 Hz with the mean 20-km time trial power output recorded for use during the remaining 74 
sessions. Fifteen min after completing the time trial, participants undertook a modified maximal 75 
exercise test.  This test consisted of cycling for one min at 80% of the mean power output recorded 76 
during the 20-km time trial with step increases in power of 35 W.min-1 until volitional fatigue. During 77 
the test, mean 15 s oxygen consumption was measured using a Parvo TrueOne metabolic cart 78 
(Parvomedics; USA). Maximal oxygen consumption was defined using the following criteria; 1) heart 79 
rate exceeding 85% of age predicted max, 2) respiratory exchange ratio greater than 1.1 and 3) a 80 
plateau in oxygen consumption (V̇O2) over a minimum of three consecutive 15 s recordings. The 81 
highest 15 s value measured within the plateau was recorded as the participant’s maximal oxygen 82 




The remaining three sessions were completed in a randomised and counterbalanced order. Each 85 
session consisted of a standardised 15 min warm-up and 20-km cycling time trial. Before the start of 86 
exercise,  participants completed a pulmonary function test after which they were provided with either 87 
one of two nasal dilation devices; internal nasal dilation (Turbine®; Rhinomed, Australia) or external 88 
nasal dilation (Breathe Right® strips; GlaxoSmithKline, USA) or no device as the control condition. 89 
Each device was fitted to the manufacturer’s specifications. Participants were then asked to rest for 90 
five min before the warm-up to allow them to become familiar with the feel of the device. The warm-91 
up started with three min of rest with the participants seated on the cycle ergometer. After this time, 92 
participants were required to complete three 5-min bouts of cycling (total 15 min) at a constant 93 
cadence of 90 rpm at 30% (82 ± 12 W), 50% (136 ± 21 W) and 70% (190 ± 29 W) of the mean 20-km 94 
time trial power output recorded during the familiarisation session. During the warm-up, V̇O2 and 95 
minute ventilation (V̇E) were recorded using a metabolic cart and Hans Rudolph Face Mask (Hans 96 
Rudolph Inc., USA) to accommodate the nasal dilation devices. Perceived exertion (Borg scale20; 97 
scale: 6 – 20; 6- no exertion at all; 20- maximal exertion) and dyspnoea (modified Borg Dyspnoea 98 
Scale21, 0- nothing at all; 10- maximal) were assessed at the completion of each stage.  Five min after 99 
completing the warm-up, participants completed a 20-km cycling time trial. During the 20-km cycling 100 
time trial, no gas collection occurred. Five min after completion of the time trial participants 101 
completed a second round of pulmonary testing. During the entire session heart rate was recorded at a 102 
frequency of 1 Hz using a Garmin heart rate monitor (Garmin Ltd., USA). Fifteen min after 103 
completing the time trial, participants were asked to rate their session perceived exertion and to rate 104 
the efficacy of the internal and external nasal dilation using a 14 cm visual analogue scale (0cm = 105 
none, 7cm = moderate and 14cm = great deal) for the questions; “Did the device help breathing a) at 106 
rest, b) during the warm-up, c) during the time trial and d) during recovery?” 107 
Respiratory muscle fatigue was assessed by maximum inspiratory pressure (cmH2O; MIP) 108 
measured using a MicroRPM™ (Respiratory Pressure Meter; CareFusion, USA). The test was 109 
conducted in triplicate with one minute recovery period between tests. Participants were required to 110 
exhale completely then while breathing through the MicroRPM, inhale as forcefully as possible, for as 111 
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long as possible during which time inspiratory pressure was continuously measured with the peak 112 
value provided at cessation.  113 
Oxygen consumption was collected throughout the standardised warm-up (three 5-min 114 
stages). Only data collected during the final two minutes of each stage were used for analysis to ensure 115 
physiological steady state. Mean V̇O2 recorded during the three min pre-warm up period was 116 
subtracted from the mean V̇O2 recorded in the final two min during each five min stage. Economy of 117 
motion was calculated using the following formula;  118 
Economy of motion = W. V̇O2-1 119 
Where W is the prescribed wattage for the stage and V̇O2 is the final two min mean oxygen 120 
consumption (L.min-1) for the corresponding stage minus the mean V̇O2 recorded during the three min 121 
warm up.  122 
All time trials commenced from a standing start with a set gear ratio of 52x17. Participants 123 
were instructed to complete the distance as fast as possible with only distance completed provided as 124 
feedback.  During the effort, perceived exertion (Borg Scale) and dyspnoea (modified Borg Dyspnoea 125 
Scale) were measured at 4-km intervals. Heart rate and power output were collected at a frequency of 126 
1 Hz using a Garmin heart rate monitor and the internal velotron software (VelotronCS, Racermate, 127 
USA); respectively.  128 
Differences in pre- and post-time trial measures of MIP, as well as 4-km measures of heart 129 
rate, perceived exertion and dyspnoea during the time trial between the Turbine®, Breathe Right® and 130 
control condition were analysed using a two-way analysis of variance (ANOVA) with repeated 131 
measures. Main effects or interactions were analysed using a Fisher’s least significant difference test. 132 
Differences in perceived effectiveness of the Turbine® and Breathe Right® nasal dilators measured at 133 
rest, during the warm-up, time trial, and recovery were analysed using a paired sample t-test. All other 134 
measures were assessed for differences between conditions using a one-way ANOVA. Statistical 135 
analyses were completed using SPSS (IBM® SPSS® Statistics, USA) with an alpha level of 0.05. 136 
Individually, 20-km time trial completion times were assessed against the smallest worthwhile change 137 
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(± 0.3%) necessary to indicate a benefit or detriment to performance 22, 23. All data are presented as 138 
mean ± standard deviations unless otherwise noted.  139 




No differences were observed in total time (p=0.65) or mean power output (p=0.78) between 142 
the Turbine® (1802.8 ± 114.4 s, 270 ± 45 W; respectively), Breathe Right® (1802.4 ± 114.0 s, 271 ± 44 143 
W; respectively) and control (1796.1 ± 113.5 s, 272 ± 44 W; respectively) conditions. Using the 144 
smallest worthwhile change to indicate a benefit or detriment to performance, when compared with the 145 
control condition, 27% of participants showed a benefit and 40% a detriment during the Turbine® trial, 146 
while 40% of participants demonstrated a benefit and 53% a detriment during the Breathe Right® trial.  147 
Heart rate, perceived exertion, and dyspnoea measured at 4-km intervals during the 20-km 148 
time trial are presented in Figure 1. A main effect for time was observed for heart rate (p<0.01), with a 149 
progressive increase in heart rate observed across all time points. Similar results were observed for 150 
perceived exertion (p<0.01) and dyspnoea (p<0.01). No differences were observed for heart rate 151 
(p=0.54), perceived exertion (p=0.66) or dyspnoea (p=0.54) between conditions at any time points.  152 
 Mean economy of motion, VE, heart rate, perceived exertion and dyspnoea during the 153 
standardised warm-up are presented in Table 1. No differences were observed for the mean economy 154 
of motion, VE, heart rate, perceived exertion between conditions at 30%, 50% or 70% of the 155 
familiarisation 20-km time trial power output. Perceived dyspnoea measured during the 30% stage was 156 
lower during the Turbine® (p=0.13) and Breathe Right® (p=0.03) compared with the control condition; 157 
however, no other differences were observed.  158 
No differences (p=0.46) were observed for the maximal inspiratory pressure measured pre- 159 
and post-time trial between the Turbine® (92 ± 26 cmH2O; 90 ± 23 cmH2O respectively), Breathe 160 
Right® (93 ± 21 cmH2O; 88 ± 20 cmH2O respectively) and control (93 ± 20 cmH2O; 89 ± 21 cmH2O 161 
respectively) conditions. 162 
 Ratings of perceived effectiveness of the Turbine® or Breathe Right® compared to the control 163 
condition are highlighted in Table 2. Perceived effectiveness of the nasal dilator during the time trial 164 
was greater during the Breathe Right® compared with the Turbine® condition. During the 20-km time 165 
trial, 40% (n = 6) of participants perceived the Turbine® nasal dilator to provide greater than a 166 
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moderate effect (score 7 out of 14), while during the Breathe Right® condition 47% (n = 7) perceived 167 
the effectiveness to be more than moderate.  In only four instances, isolated to two individuals (10% of 168 
the sample population), did a participant perceive a nasal dilator to provide more than a moderate 169 
effect and have enhanced performance during the 20-km time trial. Conversely, 33% (n = 5) and 27% 170 
(n = 4) of participants during the Turbine® and Breathe Right®  trials respectively, perceived the nasal 171 
dilator to provide less than a moderate effect while also displaying a decrease in 20-km time trial 172 
performance.  173 
 174 




The purpose of the present study was to examine the influence of internal and external nasal 177 
dilators on performance in trained cyclists. The novel findings of this study were; 1) no improvements 178 
were observed in 20-km time trial performance when using either nasal dilator compared to a control, 179 
and 2) internal and external nasal dilation did not improve economy of motion compared to the control 180 
condition. 181 
External nasal dilators can increase nasal airflow1, 17 and may provide benefits to aerobic 182 
performance;3, 16, 24 however, these performance benefits have been equivocal in the literature.1, 11, 25 183 
The use of internal nasal dilators can improve nasal airflow above external dilatation19 thus possibly 184 
providing greater stimuli to enhance performance. Our findings indicate neither internal nor external 185 
nasal dilation increased performance during a 20-km cycling time trial when compared with a control 186 
condition. This finding contradicts Tong et al.,3 who observed a 4.9% increased power output during a 187 
30-min intermittent all-out cycle exercise (20 s at 160% of V̇O2peak and 40 s of active recovery) in 188 
healthy male athletes (of various sports) under nasal dilation conditions when compared to control. 189 
These differences are likely due to the intermittent nature of the exercise prescribed by Tong et al,.3 as 190 
during the recovery periods participants would have transitioned back to predominantly nasal 191 
ventilation3 allowing the nasal dilator to have greater influence during this time, possibly enhancing 192 
aerobic recovery. Although not measured in this study, our use of a 20-km time trial would have 193 
resulted in sustained high ventilation rates26 leading to greater oral ventilation13 thus reducing the 194 
impact of nasal dilation on overall performance.  195 
During moderate duration endurance based events, conservation of energy is essential.24 With 196 
increasing intensity, a concurrent increase in ventilation is associated with a greater oxygen cost of 197 
breathing and subsequently greater energy consumption.27 The ability to unload respiratory muscles 198 
during set intensity exercise can reduce the energy cost of breathing1, 2, 25, thus increasing economy of 199 
motion. Our data indicates internal and external nasal dilation had no influence on the economy of 200 
motion measured at 30%, 50% and 70% of each participant’s 20-km time trial power output (Table 1). 201 
Our findings are not consistent with Griffin et al.,24 who observed a decrease in V̇O2 of participants 202 
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cycling at 100 W (1.3 L.min-1 with device VS. 1.4 L.min-1 with no device) and 150 W (1.9 L.min-1 203 
with device VS. 2.0 L.min-1 with no device) while using external nasal dilation. During this study, 204 
participants were instructed to switch from nasal breathing to oral-nasal breathing when they felt it 205 
necessary thus increasing the awareness of their breathing patterns.24 It is possible changes in 206 
breathing pattern may have influenced the measure of V̇O2.4, 24, 27 In the current study, no such 207 
instructions were provided as we allowed participants to change naturally from nasal to oral-nasal 208 
breathing.    209 
Although neither the internal or external nasal dilation provided a benefit to performance, it is 210 
possible such manipulation could still result in both physiological and perceptual benefits through the 211 
influence of bio-feedback.28, 29 Sustained heavy exercise can increase heart rate and dyspnoea5, 6, 12 212 
which can increase perceived exertion.5, 6, 26 During the 20-km time trial, heart rate and perceived 213 
dyspnoea and exertion increased in a time-dependent manner in all conditions (Figure 1); however, 214 
neither nasal dilation condition resulted in a decrease in heart rate or perceived dyspnoea or exertion 215 
compared with the control. Furthermore, during the standardised warm up neither nasal dilator 216 
resulted in observable differences in heart rate or perceived exertion, at any intensity (Table 1). Of 217 
note, perceived dyspnoea at the lowest warm up intensity was less in both nasal dilation conditions 218 
when compared with the control. Notwithstanding this difference, heart rate, perceived exertion and 219 
dyspnoea recorded during both the warm up and time trial indicates neither nasal dilator is likely to 220 
provide a physiological or perceptual benefit through means of bio-feedback.    221 
The current study provides novel information into the efficacy of internal and external nasal 222 
dilators on physiological changes and performance during a 20-km cycling time trial. However, we 223 
acknowledge issues with the methodology used in this study, specifically the lack of a sham treatment 224 
condition, could have influenced the performance measures through either a placebo or nocebo effect 225 
30. Unfortunately, the mechanical nature of both the Turbine® and Breathe Right® nasal dilators would 226 
not allow for a sham treatment as it was not possible to apply either device with a genuine feel without 227 
also resulting in nasal dilation. Nevertheless, individual performance and perceived effectiveness data 228 
indicate a lack of placebo effect as only two of the 15 participants reported the devices to provide a 229 
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benefit and demonstrated improved performance. Furthermore, negative assessment of the device also 230 
did not appear to influence performance outcomes as 33% of participants in the Turbine® condition 231 
and 27% in the Breathe Right® condition rated the device to provide less than a moderate benefit and 232 
performed worse compared to the control condition.     233 
Conclusion 234 
The use of nasal dilation assisting devices, irrespective of the mechanism (internal or 235 
external), does not provide performance enhancement during a 20-km cycling time trial. While it has 236 
previously been suggested that nasal dilation can unload respiratory muscle thus reduce the oxygen 237 
cost of breathing, our findings do not support this claim. Furthermore, individual responses to both the 238 
Turbine® and Breathe Right® nasal dilators do not indicate the presence of a placebo or nocebo effect. 239 
The efficacy of such devices in a competitive sports setting should be questioned.  240 
Practical implications  241 
 During a 20-km cycling time trial (~30 min) neither internal or external nasal dilation are 242 
likely to provide any performance benefits.  243 
 Perceived exertion is not influenced by nasal dilation during a 20-km cycling time trial.  244 
 Neither internal or external nasal dilation is likely to improve economy of motion while 245 
cycling at moderate intensity. 246 
Acknowledgments 247 
This study was completed using funding provided by RhinoMed Ltd., who manufactures the Turbine® 248 




1. O'Kroy JA. Oxygen uptake and ventilatory effects of an external nasal dilator during 251 
ergometry. Med Sci Sports Exerc 2000; 32(8):1491-1495. 252 
2. Holm P, Sattler A, Fregosi RF. Endurance training of respiratory muscles improves cycling 253 
performance in fit young cyclists. BMC Physiol 2004; 4:9. 254 
3. Tong TK, Fu FH, Chow BC. Effect of nostril dilatation on prolonged all-out intermittent 255 
exercise performance. J Sports Med Phys Fitness 2001; 41(2):189-195. 256 
4. Bye PT, Esau SA, Walley KR, et al. Ventilatory muscles during exercise in air and oxygen in 257 
normal men. J Appl Physiol Respir Environ Exerc Physiol 1984; 56(2):464-471. 258 
5. Mador MJ, Acevedo FA. Effect of respiratory muscle fatigue on subsequent exercise 259 
performance. J Appl Physiol (1985) 1991; 70(5):2059-2065. 260 
6. Romer LM, Polkey MI. Exercise-induced respiratory muscle fatigue: implications for 261 
performance. J Appl Physiol (1985) 2008; 104(3):879-888. 262 
7. Guenette JA, Sheel AW. Exercise-induced arterial hypoxaemia in active young women. Appl 263 
Physiol Nutr Metab 2007; 32(6):1263-1273. 264 
8. Romer LM, McConnell AK, Jones DA. Inspiratory muscle fatigue in trained cyclists: effects 265 
of inspiratory muscle training. Med Sci Sports Exerc 2002; 34(5):785-792. 266 
9. Wagner PD. New ideas on limitations to VO2max. Exerc Sport Sci Rev 2000; 28(1):10-14. 267 
10. Meissner HH, Santiago SM, Koyal SN, et al. Characteristics of nasal airflow and the effect of 268 
a nasal dilator in normal human subjects. Respir Physiol 1999; 115(1):95-101. 269 
11. O'Kroy JA, James T, Miller JM, et al. Effects of an external nasal dilator on the work of 270 
breathing during exercise. Med Sci Sports Exerc 2001; 33(3):454-458. 271 
12. Romer LM, McConnell AK, Jones DA. Effects of inspiratory muscle training upon recovery 272 
time during high intensity, repetitive sprint activity. Int J Sports Med 2002; 23(5):353-360. 273 
13. Fregosi RF, Lansing RW. Neural drive to nasal dilator muscles: influence of exercise intensity 274 
and oronasal flow partitioning. J Appl Physiol (1985) 1995; 79(4):1330-1337. 275 
15 
 
14. Kirkness JP, Wheatley JR, Amis TC. Nasal airflow dynamics: mechanisms and responses 276 
associated with an external nasal dilator strip. Eur Respir J 2000; 15(5):929-936. 277 
15. Wells GD, Plyley M, Thomas S, et al. Effects of concurrent inspiratory and expiratory muscle 278 
training on respiratory and exercise performance in competitive swimmers. Eur J Appl Physiol 279 
2005; 94(5-6):527-540. 280 
16. Dinardi RR, de Andrade CR, Ibiapina Cda C. Evaluation of the effectiveness of the external 281 
nasal dilator strip in adolescent athletes: a randomized trial. Int J Pediatr Otorhinolaryngol 282 
2013; 77(9):1500-1505. 283 
17. Dinardi RR, de Andrade CR, Ibiapina Cda C. External nasal dilators: definition, background, 284 
and current uses. Int J Gen Med 2014; 7:491-504. 285 
18. Seto-Poon M, Amis TC, Kirkness JP, et al. Nasal dilator strips delay the onset of oral route 286 
breathing during exercise. Can J Appl Physiol 1999; 24(6):538-547. 287 
19. Peltonen LI, Vento SI, Simola M, et al. Effects of the nasal strip and dilator on nasal 288 
breathing--a study with healthy subjects. Rhinology 2004; 42(3):122-125. 289 
20. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14(5):377-290 
381. 291 
21. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for 292 
the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989; 76(3):277-282. 293 
22. Hopkins WG, Hawley JA, Burke LM. Design and analysis of research on sport performance 294 
enhancement. Med Sci Sports Exerc 1999; 31(3):472-485. 295 
23. Hickey MS, Costill DL, McConell GK, et al. Day to day variation in time trial cycling 296 
performance. Int J Sports Med 1992; 13(6):467-470. 297 
24. Griffin JW, Hunter G, Ferguson D, et al. Physiologic effects of an external nasal dilator. 298 
Laryngoscope 1997; 107(9):1235-1238. 299 
25. Gehring JM, Garlick SR, Wheatley JR, et al. Nasal resistance and flow resistive work of nasal 300 




26. Nicolo A, Marcora SM, Sacchetti M. Respiratory frequency is strongly associated with 303 
perceived exertion during time trials of different duration. J Sports Sci 2016; 34(13):1199-304 
1206. 305 
27. Vella CA, Marks D, Robergs RA. Oxygen cost of ventilation during incremental exercise to 306 
VO2max. Respirology 2006; 11(2):175-181. 307 
28. Hatfield BD, Spalding TW, Mahon AD, et al. The effect of psychological strategies upon 308 
cardiorespiratory and muscular activity during treadmill running. Med Sci Sports Exerc 1992; 309 
24(2):218-225. 310 
29. Caird SJ, McKenzie AD, Sleivert GG. Biofeedback and relaxation techniques improves 311 
running economy in sub-elite long distance runners. Med Sci Sports Exerc 1999; 31(5):717-312 
722. 313 
30. Pollo A, Carlino E, Benedetti F. Placebo mechanisms across different conditions: from the 314 
clinical setting to physical performance. Philos Trans R Soc Lond B Biol Sci 2011; 315 
366(1572):1790-1798. 316 




Table 1. Mean economy of motion, minute ventilation (VE), heart rate (HR), ratings of perceived 319 
exertion (RPE) and dyspnoea recorded during the standardised warm-up at 30%, 50% and 70% of 320 
familiarisation mean time trial (Fam. TT) power output. 321 
 Turbine® Breathe Right® Control P value 
Economy of motion 
(W.LO2-1) 
    
30% 53.9 ± 5.8 53.2 ± 7.8 53.9 ± 7.2 0.86 
50% 65.7 ± 5.6 64.2 ± 8.5 65.3 ± 7.6 0.67 
70% 69.9 ± 3.5 68.1 ± 7.9 69.1 ± 6.5 0.74 
VE (L.min-1) 
    
30% 29.0 ± 4.0 29.7 ± 4.6 29.4 ± 3.9 0.75 
50% 41.0 ± 6.4 42.3 ± 7.1 41.5 ± 5.8 0.61 
70% 54.9 ± 9.6 56.4 ± 9.8 55.0 ± 9.3 0.61 
Mean HR (bpm) 
    
30% 100 ± 18 97 ± 9 100 ± 22 0.74 
50% 117 ± 19 114 ± 12 115 ± 16 0.75 
70% 130 ± 13 127 ± 10 126 ± 8 0.26 
RPE (units) 
    
30% 8 ± 1 8 ± 1 8 ± 1 0.87 
50% 10 ± 1 10 ± 1 10 ± 1 0.48 
70% 12 ± 1 12 ± 1 11 ± 2 0.14 
Dyspnoea (units) 
    
30% 0.7 ± 0.4a 0.7 ± 0.2a 1.1 ± 0.6 0.02 
50% 1.8 ± 0.8 1.7 ± 0.9 2.0 ± 0.7 0.14 
70% 2.7 ± 1.0 2.8 ± 1.0 2.8 ± 0.7 0.71 
a Less (p < 0.05) than control condition.  322 
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Table 2. Perceived effectiveness of Turbine® and Breathe Right® Nasal dilation conditions when 323 
compared with the control condition measured on a 14cm visual analogue scale. 324 
 Turbine® Breathe Right® P value 
At Rest 4.3 ± 3.5 5.0 ± 3.2 0.40 
During the Warm-up 4.3 ± 2.4 5.4 ± 3.0 0.18 
During the TT 3.7 ± 3.2 6.1 ± 4.3 0.02 
During Recovery 3.6 ± 2.7 5.4 ± 4.0 0.06 
Note. Recovery = 15 min post time trial. Response to question: “Did the device help breathing?”     325 
Figure Captions 326 
Figure 1. Mean heart rate (A), ratings of perceived exertion (RPE; (B)) and dyspnoea (C) measured at 327 
4-km intervals during the 20-km cycling time trial in the Turbine® (□), Breathe Right® (○) and control 328 
(●) conditions. a Main effect for time: all time points greater than preceding time points. 329 
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